Logo-bi
Review
Leila Rostamizadeh ORCID, Ommoleila Molavi* ORCID, Mohsen Rashid, Fatemeh Ramazani, Behzad Baradaran, Afsaneh Lavasanaifar, Raymond Lai
BioImpacts. 2022;12(3): 261-290. doi: 10.34172/bi.2022.23896
PMCID: PMC9124882     PMID: 35677663     Scopus ID: 85132074584    
In this paper, we will review the application of the four most widely studied TLR agonists including agonists of TLR3, 4, 7, and 9 in cancer immunotherapy.


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2024): 20% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMedPubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science IndicatorsEmbase; EBSCOhost; CAS: DOAJSHERPA/RoMEO
Member of COPE
Follower of ICMJE
Permission: Creative Commons